Ucl Business Plc

Vitaflo International Ltd

Robin Simon Brooke Williams

Matthew Charles Walker

Simon Heales

Patricia Rutherford

Simon Eaton

Maura Louise ODonnell

Aziza Khabbush

Matthew Walker

A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a Cbackbone, optionally branched with a Calkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a Cbackbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the γ carbon of R1, or of only single methyl groups at both the β and ω-1 carbons of R1, and provided that when R1 is an alkyl group having a Cor Cbackbone, the branching does not consist only of a propyl group at the a carbon of R1.

Therapeutic use of compounds

A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a Cbackbone, optionally branched with a Calkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a Cbackbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the &#x3b3; carbon of R1, or of only single methyl groups at both the &#x3b2; and &#x3c9;-1 carbons of R1, and provided that when R1 is an alkyl group having a Cor Cbackbone, the branching does not consist only of a propyl group at the a carbon of R1.

A composition comprising a decanoic acid to octanoic acid ratio of 70:30 to 90:10 wt/wt for use in treating epilepsy or controlling epileptic seizures.

Composition for use in the treatment of epilepsy

A compound having the formula (I) R1-COOH wherein R1 is an alkyl or alkenyl group having a Cbackbone, optionally branched with a Calkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof, wherein the backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a Cbackbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the &#x3b3; carbon of R1, or of only single methyl groups at both the &#x3b2; and &#x3c9;&#x2212;1 carbons of R1, and provided that when R1 is an alkyl group having a Cor Cbackbone, the branching does not consist only of a propyl group at the a carbon of R1, for use in the treatment or prevention of a disease or a biomedical condition selected from seizure-related disorders, bipolar disorders, mania, depression, migraine, attention deficit hyperactivity disorders, latent HIV infection, Alzheimer's disease, chorea, schizophrenia, ischemia, cancer and fatal blood loss.

Growing community of inventors

Egham, United Kingdom

Robin Simon Brooke Williams